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Abstract
Mitochondrial dysfunction has a recognised role in the progression of Alzheimer's dis-
ease (AD) pathophysiology. Cerebral perfusion becomes increasingly inefficient through-
out ageing, leading to unbalanced mitochondrial dynamics. This effect is exaggerated 
by amyloid β (Aβ) and phosphorylated tau, two hallmark proteins of AD pathology. A 
neuroprotective role for the adipose-derived hormone, leptin, has been demonstrated in 
neuronal cells. However, its effects with relation to mitochondrial function in AD remain 
largely unknown. To address this question, we have used both a glucose–serum-deprived 
(CGSD) model of ischaemic stroke in SH-SY5Y cells and a Aβ1–42-treatment model of AD 
in differentiated hippocampal cells. Using a combination of 5,5’,6,6’-tetrachloro-1,1’,3,3’-
tetraethylbenzimidazolylcarbocyanine iodide (JC-1) and MitoRed staining techniques, 
we show that leptin prevents depolarisation of the mitochondrial membrane and ex-
cessive mitochondrial fragmentation induced by both CGSD and Aβ1–42. Thereafter, we 
used ELISAs and a number of activity assays to reveal the biochemical underpinnings of 
these processes. Specifically, leptin was seen to inhibit up-regulation of the mitochon-
drial fission protein Fis1 and down-regulation of the mitochondrial fusion protein, Mfn2. 
Furthermore, leptin was seen to up-regulate the expression and activity of the antioxi-
dant enzyme, monoamine oxidase B. Herein we provide the first demonstration that lep-
tin is sufficient to protect against aberrant mitochondrial dynamics and resulting loss of 
function induced by both CGSD and Aβ1–42. We conclude that the established neuropro-
tective actions of leptin may be facilitated through regulation of mitochondrial dynamics.
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1  | INTRODUC TION
The high energy demands of neuronal cells mean that they are par-
ticularly reliant on mitochondrial dynamics and function (Safiulina & 
Kaasik, 2013). Fission and fusion dynamics promote the distribution of 
mitochondria along axons so that mitochondria can deliver energy ef-
ficiently to synapses-distant locations with high energy requirements 
(Li, Okamoto, Hayashi, & Sheng, 2004; Westermann, 2012). Aberrant 
mitochondrial fission and fusion dynamics lead to altered mitochon-
drial morphology and distribution, which damages the energy supply 
by impeding mitochondrial function. Abnormal mitochondrial mor-
phology caused by aberrant dynamics represents an essential common 
pathway which regulates, or intensifies, mitochondrial dysfunction in 
neurodegenerative disease (Su et al., 2010). Extensive evidence sup-
ports the contribution of abnormal mitochondrial function to cellular 
energy depletion (Divya, Amandine, & Ken, 2013; Flint, 1995), oxida-
tive stress and neuronal loss (Lin & Beal, 2006), which are key features 
of neurodegenerative diseases (Burté, Carelli, Chinnery, & Yu-Wai-
Man, 2015; Johri & Beal, 2012; Lin & Beal, 2006).
Compelling evidence from both in vivo and in vitro studies 
shows that amyloid-precursor protein (APP) and/or Aβ causes 
mitochondrial dysfunction and morphological changes (Reddy & 
Beal, 2008). APP and/or Aβ block the import of functional pro-
teins into mitochondria by localizing to mitochondrial membranes 
(Crouch et al., 2005; Sirk et al., 2007), disrupting the energy 
metabolism chain and increasing reactive oxygen species (ROS) 
production by interacting with mitochondrial enzymes (Casley, 
Canevari, Land, Clark, & Sharpe, 2002; Cha et al., 2012), even-
tually causing mitochondrial dysfunction and neuronal apoptosis 
(Reddy & Beal, 2008). In post-mortem AD brains the mRNA for 
complex I genes is down-regulated, while the genes for complex 
III and IV constituents are up-regulated revealing molecular de-
fects in oxidative phosphorylation and thus mitochondrial func-
tion (Manczak, Park, Jung, & Reddy, 2004); and similar results 
are observed in APP mutant mice (Tg2576) (Reddy et al., 2004). 
In vitro studies demonstrate that Aβ peptides (1–42, 25–35) dam-
age mitochondrial membrane potential (ΔΨm), increase ROS and 
cause abnormal mitochondrial fragmentation in several cell lines 
and also in primary neuronal cultures (Barsoum et al., 2006; Cha 
et al., 2012). A recent study on Alzheimer's disease brains revealed 
a complex dysregulation of the activities of specific mitochondrial 
enzymes, monoamine oxidases A and B (MAO A and B) and further 
confirmed that mRNA, protein and activity of the MAOs varied in-
dependently (Quartey et al., 2018). These observations suggest a 
central role for mitochondria in neurodegeneration that warrants 
investigation.
The adipose-derived hormone, leptin, is known for its cen-
tral role in the regulation of energy metabolism. Emerging lines of 
evidence indicate direct and indirect links between leptin and mi-
tochondria function; however, the vast majority of the empirical 
studies have been carried out in non-neuronal lineages. It has been 
found that leptin regulates mitochondrial respiration in prostate 
cancer cells (Calgani et al., 2016). Leptin treatment ameliorates the 
inhibition of mitochondrial respiration in leptin-deficient ob/ob mice 
(Finocchietto et al., 2011). Cultured human adipose tissue fragments 
inhibit mitochondrial respiration in HCT116 colon cancer cells, an 
effect purported to be regulated by leptin (Yehuda-Shnaidman et al., 
2013). Leptin is also involved in the regulation of mitochondrial en-
zymes, such as manganese superoxide dismutase in hippocampal 
neurons (Guo, Jiang, Xu, Duan, & Mattson, 2008) and proxisome 
proliferator-activated receptor γ coactivator 1 (PGC1-α) in breast 
cancer cells (Blanquer-Rosselló, Santandreu, Oliver, Roca, & Valle, 
2015). All of these mitochondrial enzymes have been linked to neu-
rodegenerative changes in a number of disorders. In addition, other 
mitochondrial enzymes, such as monoamine oxidases, have been in-
tricately linked to both Parkinson's and Alzheimer's Diseases (Naoi, 
Riederer, & Maruyama, 2016); and are proposed therapeutic targets 
in such conditions (Matthew et al., 2019). However, the potential 
role of leptin in the regulation of the monoamine oxidases remains 
unknown.
Leptin also has a number of other beneficial effects on neu-
ronal function and survival (Doherty, Oldreive, & Harvey, 2008; 
McGregor & Harvey, 2019). Neuroprotection by leptin has been de-
scribed in models of major neurodegenerative diseases such as AD 
(Doherty, Beccano-Kelly, Yan, Gunn-Moore, & Harvey, 2013; Perez-
Gonzalez et al., 2011; Weng et al., 2007), although the underlying 
molecular mechanism remains to be fully understood. Despite the 
maladaptive changes to mitochondrial dynamics and function are 
thought to play in the onset and progression of AD, the potentially 
important link between leptin and mitochondria in AD has yet to 
be explored.
Stroke is associated with AD in elderly individuals (Honig et al., 
2003). Stroke significantly and increases the risk of AD devel-
opment independent of genetic factors (Zhou et al., 2015), and 
disrupted cerebral perfusion has been suggested to contribute to 
AD neuropathological changes (Austin et al., 2011). Serum star-
vation-induced neuronal apoptosis is regarded as an established 
AD-related insult in vitro (Kariya, Takahashi, Hirano, & Ueno, 
2003). Serum deprivation leads to the increased secretion of 
β-secretase that is an initiator in the formation of toxic Aβ pep-
tides (Stavropoulou, Mavrofrydi, Saftig, & Efthimiopoulos, 2017). 
Chronic cerebral hypoperfusion exaggerates tau phosphorylation 
in tau transgenic mice, however, this is attenuated by the expres-
sion of the signalling competent form of the leptin receptor (Ob-
Rb), and activation of its downstream signalling pathways (AKT/
pAKT) (Shimada et al., 2019). Ob-Rb is up-regulated in brains from 
individuals with AD and cerebrovascular diseases, further indicat-
ing an endogenous neuroprotective role of leptin in the crosstalk 
between stroke and AD (Shimada et al., 2019; Terao et al., 2008). 
Exploring the effects of leptin in both stroke and AD models will 
boost our understanding of the neuroprotective role of leptin 
and its relationship with mitochondrial function. In particular, ex-
ploring the protective effects of leptin in a combined glucose and 
serum deprivation (CGSD) model will further highlight the neuro-
protective effects of leptin in the early stages of AD. Therefore, 
in this study, we examined the effects of leptin on mitochondrial 
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dynamics, morphology and function in CGSD SH-SY5Y human 
neuroblastoma cells, an established model of ischaemic stroke 
(Lorenz et al., 2009), and in Aβ1–42-treated differentiated HT-22 
hippocampal neuronal cells as an AD model.
2  | METHODS
2.1 | Materials
Unless otherwise stated all materials and reagents were purchased 
from Sigma, UK.
2.2 | Cell culture
Ethical approval to work with the cell lines in these experi-
ments was obtained from the University of St Andrews School of 
Psychology & Neuroscience Ethics committee, approval number 
PS10538_Doherty. The cell lines used in this study are not listed 
as a commonly misidentified cell line by the International Cell Line 
Authentication Committee and the line was last ensured for purity 
in 2017. The human neuroblastoma cell line SH-SY5Y (#94030304, 
2017; RRID:CVCL_0019) and mouse hippocampal neuronal cell line 
HT-22 (Merck, #SCC129; 2017; RRID:CVCL_0321) were cultured in 
10% (v/v) heat-inactivated calf serum (C8056; Fisher Scientific) in 
Dulbecco's modified Eagle’s medium (21885108; Fisher Scientific) 
supplemented with 4500 mg/L glucose and 10 mg/ml penicillin/
streptomycin in a 37°C incubator which provides a humidified 5% 
CO2 atmosphere. Cells were plated at densities of 2 × 10
4 and 
5 × 104 on 96-, and 24-well Nunclon coated plates, with or without 
13 mm borosilicate glass coverslips (CC7672-7548, CC7672-7458; 
VWR). Also, they were plated at densities of 3 × 105 and 6 × 105 
on 35 and 60 mm Nunclon-coated culture dishes (153066158015; 
VWR), respectively. SH-SY5Y cells were grown to 70% conflu-
ence before treatment. Undifferentiated SH-SY5Y cells were then 
maintained in 10% medium as a positive control, or subjected to 
combined serum and glucose deprivation (CGSD; 0% calf serum 
and 1000 mg/L glucose). CSGD cultures were supplemented with 
leptin (L4146, 0.1–10 nM) for between 24 and 72 hr depending on 
the experimental paradigm. All cell lines were used between pas-
sage 6 and 20.
2.3 | Differentiation of HT-22 cells
HT-22 cells were grown to 70% confluence before differentiation. 
Cells were differentiated using 100 μM N6,2’-O-dibutyryladenosine 
3’,5’-cyclic monophosphate sodium salt (dbcAMP) (A9501) in 
Dulbecco's modified Eagle’s medium supplemented with 2% (v/v) 
serum replacement −2 (S9388), 4500 mg/L glucose and 10 mg/ml 
penicillin/streptomycin in a 37°C incubator. After 24 hr differentia-
tion, HT-22 cells were then maintained in 2% serum replacement-2 
medium as a control, or treated with 10 μM Aβ1–42 (A9810) with or 
without leptin (0.1–10 nM) for 24 hr.
2.4 | Protein preparation and ELISA assay
Protein was extracted into 500 µl Tris buffered saline (T6664) sup-
plemented with 1% Triton X-100 (X-100) and 5 µl protease inhibitor 
cocktail (S8820). A micro-Bradford assay was performed to meas-
ure approximate protein concentration to allow for equal protein 
loading. ELISA was performed to detect changes in protein expres-
sion relative to a loading control. The antibodies for ELISA were as 
follows: anti-Mfn1 (1:10,000; Santa Cruz, Insight Biotechnologies; 
#sc-166644, RRID:AB_2142616), anti-Mfn2 (1:5,000; Santa Cruz; 
#sc-515647, RRID:AB_2811176), anti-Drp1 (1:1,000; Santa Cruz; 
#sc-101270, RRID:AB_2093545), anti-Fis1 (1:2000; Santa Cruz; 
#sc-98900, RRID:AB_2246809), anti-VDAC1 (1:5,000; Santa Cruz; 
#sc-390996, RRID:AB_2750920), anti-MAOA (1:10,000; Santa Cruz; 
#sc-18396, RRID:AB_2137263), anti-MAOB (1:1,000; Santa Cruz; 
#c-515354, RRID:AB_2819030), anti-NRF1 (1:5,000; Santa Cruz; #sc-
23624, RRID:AB_10613096), anti-PGC1α (1:5,000; Santa Cruz; # sc-
517380, RRID:AB_2755043), anti-α-tubulin (1:2000; Sigma-Aldrich; 
#T5168, RRID:AB_477579), HRP-conjugated anti-mouse (1:10,000; 
Sigma-Aldrich; #A9044, RRID:AB_258431), HRP-conjugated anti-goat 
(1:5,000; Sigma-Aldrich; #A8919, RRID:AB_258425), HRP-conjugated 
anti-rabbit (1;10,000; Santa Cruz; # sc-2357, RRID:AB_628497). In 
ELISAs, anti-VDAC1 was used as mitochondrial loading control an-
tibody and anti-α-tubulin was used as cytoplasmic loading control 
antibody to identify any loading difference across samples. After nor-
malising for any loading differences, the mean absorbance of each 
sample was further normalised to the control for each experiment.
2.5 | MitoRed staining and Immunocytochemistry
9- [2-(4'-Methylcoumarin-7'-oxycarbonyl) phenyl]-3,6-bis (diethyl-
amino) xanthylium chloride (MitoRed; #53271) is a cell membrane 
permeable rhodamine-based dye that is used to stain mitochondria. 
Cells were treated with pre-warmed cell culture medium containing 
1 µM MitoRed and returned to the incubator for 45 min. Following 
fixation in neutral buffered formalin (NBF) (from formaldehyde so-
lution 15,512) for 15 min, cells were washed three times in phos-
phate buffered saline (PBS BR0014G). 10% horse serum was added 
and incubated for 10 min to block non-specific antibody bind-
ing. Cells were probed with mouse anti-Mfn2 (1:2000; Santa Cruz 
#sc-515467, RRID:AB_2811176) or rabbit anti-Fis1 (1:500; Santa 
Cruz #sc-98900; RRID:AB_2246809z) overnight at 4°C followed 
by staining with FITC-conjugated anti-mouse IgG (1:200, FI-2020, 
RRID:AB_2336185) or FITC-conjugated anti-rabbit IgG (1:200, FI-
1000, RRID:AB_2336197) respectively for 2 hr at room temperature. 
After washing, the stained coverslips were mounted in fluorescent 
mountant (1% w/v N-propyl-gallate (O2370) dissolved in 80% v/v 
glycerol (G5516)+20%v/v PBS) onto microscope slides, sealed with 
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nail polish and imaged at an excitation wavelength of 495 nm on a 
Zeiss Axio MR2 microscope (RRID:SCR_016980). Images were cap-
tured using the embedded Zen software (RRID:SCR_013672).
2.6 | Mitochondrial morphology analysis
Mitochondrial morphology was quantified using ImageJ software 
(RRID:SCR_002285). Briefly, a polygon box was drawn around each 
individual cell. The image background of individual cells was pre-pro-
cessed. After thresholding images, mitochondrial individual particles 
were analysed for counts, area and perimeter. From these values, 
we calculated indices of mitochondrial fragmentation and intercon-
nectivity. The index of mitochondrial fragmentation was calculated 
from the ratio of the count of individual mitochondria to the total mi-
tochondrial area within the cell. These measure have been described 
previously (Connolly et al., 2018; Dagda et al., 2009; Senyilmaz et al., 
2015). The mean area was divided by the mean perimeter of all ana-
lysed particles within individual cells to obtain an index of mitochon-
drial interconnectivity. As quantitative rather than subjective image 
analyses were carried out throughout this paper, no blinding was 
performed.
2.7 | JC-1 assay
To detect variation of the mitochondrial membrane potential 
(ΔΨm), a cytofluorimetric, lipophilic cationic dye, 5,5’,6,6’-tetra-
chloro-1,1’,3,3’-tetraethylbenzimidazolylcarbocyanine iodide (JC-1, 
#MAK159) was used. Cells were plated on 13 mm borosilicate glass 
coverslips (0111530, Pyramid Innovation) and treated as appropri-
ate for experiments. Twenty-five microlitre of 200× JC-1 stock so-
lution (1 mg/ml) together with 1 ml of 5× JC-1 staining buffer was 
diluted in 4 ml of ultrapure water. The diluted staining solution was 
mixed with cell culture medium at a 1:1 ratio before being added 
into each well. After being incubated for 45 min, the coverslips were 
mounted in cell culture medium for live imaging at × 40 and × 63 
magnification. As the red fluorescence fades more quickly than the 
green, we imaged the red channel (λex = 540 nm) first and then the 
green quickly afterwards (λex = 490 nm) and overlaid the images. 
The intensity ratio of red to green fluorescence was calculated to 
monitor the ΔΨm.
2.8 | MAO activity assay
MAO activity was determined as previously (Zhou, Diwu, Panchuk-
Voloshina, & Haugland, 1997). Briefly, SH-SY5Y cells were washed 
once in PBS and harvested after 24 hr treatment. Isolation of mi-
tochondria was carried out using a mitochondrial isolation kit 
(#MITOISO2) in accordance with manufacturer's instructions. 
Enriched mitochondrial pellets were suspended in a final volume 
of 100 µl 50 mM potassium phosphate (P5655) pH 7.5, mixed with 
50 µl tyramine substrate (4 mM) and 50 µl Amplex Red (90101, 
80 µM) with Horseradish Peroxidase (5 Units/ml). The time-depend-
ent increase in resorufin fluorescence was measured at 30°C using 
excitation at 535 nm and emission at 595 nm in a fluorescence mi-
croplate reader (Molecular Devices FilterMax F5 multi-modal micro-
plate reader).
2.9 | Determination of cell viability
Lactate dehydrogenase assay (LDH assay) and crystal violet assay 
were performed as described previously (Malekizadeh et al., 2017). 
The absorbance was determined with a Biohit BP100 plate reader. 
Readings were collated by conditions and normalized to control 
to eliminate density differences during plating among individual 
experiments.
2.10 | Statistical analysis
These experiments were exploratory with no pre-determined end-
point and no data was excluded from the analyses. All statistical 
analysis was carried out using SPSS 23 (IBM corp.). GraphPad PRISM 
5 (Graph Pad Inc.) was used to generate graphs. No samples size 
calculations were performed. In all experiments, data are expressed 
as mean ± SEM. After testing for normality using a D’Agnostino-
Pearson omnibus normality test, statistical analyses were performed 
using either one-way analysis of variance (ANOVA) with Dunnett's/
Dunn's post hoc test for comparisons between multiple groups or an 
independent-samples t-test for comparisons between two groups. 
Data that was not normally distributed was analysed by a Mann–
Whitney U test. Outliers were defined as data points more than two 
standard deviations from the mean. Data points were excluded from 
the calculations for Figures 1d, 2e,f, 3e,f, 5c and 6c. p < .05 was con-
sidered significant.
3  | RESULTS
3.1 | Leptin prevent depolarization of the 
mitochondrial membrane
ΔΨm is an important indicator of mitochondrial function and thus 
cellular health; and we evaluated this using JC-1 dye. In Figure 1, 
representative images of ΔΨm variations in both CGSD SH-SY5Y 
cells (Figure 1a–c) and Aβ1–42-treated differentiated hippocampal 
HT-22 neurons (Figure 1e–g), with or without leptin treatment for 
24 hr are shown. In healthy cells, JC-1 accumulates in the mitochon-
dria as a function of ΔΨm and forms red fluorescent aggregates in 
the mitochondrial matrix. JC-1 remaining in the cytosol, indicative 
of membrane damage, is observed as green fluorescent monomers. 
In each group, the intensity ratios of JC-1 aggregates (red) to mono-
mers (green) of each group were measured using image analysis 
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(Figure 1d,h). In keeping with the previous literature using such anal-
yses, each cell is regarded as an independent event (Connolly et al., 
2018). In CGSD SH-SY5Y cells, leptin treatment resulted in more 
red fluorescent aggregates (Figure 1b,c) compared to CGSD in the 
absence of leptin (Figure 1a). Application of leptin (0.1 nM) signifi-
cantly increased ΔΨm in comparison with CGSD cells that had not 
been treated with leptin (p < .001, Kruskal–Wallis with Dunn's post 
hoc test; n > 180 cells per condition from three independent experi-
ments, Figure 1d).
Previous studies indicated that Aβ1–42 reduces ΔΨm in un-
differentiated HT-22 cells that are still in the cell cycle (Cha et al., 
2012). Our study expanded on this finding to show that Aβ1–42 re-
duces ΔΨm in post-mitotic differentiated HT-22 hippocampal cells 
(Figure 1e). In accordance with our data for the CGSD cells above, 
leptin treatment promoted the accumulation of JC-1 into mitochon-
dria compared to Aβ1–42-treated cells that had not been co-treated 
with leptin (Figure 1e–g), indicating increased ΔΨm. Quantitative 
image analysis demonstrated that both 10 and 0.1 nM leptin signifi-
cantly ameliorated reductions to ΔΨm induced by Aβ1–42 (p < .05, 
p < .001 one-way ANOVA with Dunn's post hoc test; n > 60 cells per 
condition from three independent experiments, Figure 1h). Taken to-
gether these data show that leptin ameliorates reductions to ΔΨm in 
neuronal models of stroke and AD.
3.2 | Leptin prevents increased mitochondrial 
fragmentation in an in vitro ischemia model
Given the above beneficial effects of leptin on ΔΨm, we next deter-
mined whether leptin modulates mitochondrial morphology, using 
MitoRed staining. Representative images of CGSD SHSY5Y cells 
after 72 hr treatment, with different mitochondrial morphologies 
are shown (Figure 2a–d). In untreated control cells, mitochondrial 
morphology is predominantly short and tubular (Figure 2a). CGSD 
for 72 hr resulted in an increase in smaller and rounded mitochon-
dria in comparison to control, (Figure 2b). Leptin co-treatment at 10 
or 0.1 nM for 72 hr prevented the CGSD-induced fragmentation, 
comparably increasing the interconnectivity of the mitochondrial 
network (Figure 2c,d).
According to the scoring system reported in previous studies 
(Connolly et al., 2018; Dagda et al., 2009; Senyilmaz et al., 2015), 
indices of mitochondrial count, size, fragmentation and intercon-
nectivity were calculated. By normalizing the count to the total mi-
tochondrial area, the index of fragmentation was obtained (count/
area). The average mitochondrial size was divided by the average mi-
tochondrial perimeter, yielding the index of interconnectivity (mean 
area/mean perimeter). The index of interconnectivity is sensitive for 
normal to highly interconnected mitochondria, while the index of 
F I G U R E  1   Leptin improves both combined glucose and serum deprivation (CGSD)-mediated early ΔΨm damage and Aβ1–42-mediated 
ΔΨm depolarization. ΔΨm was monitored with 5,5’,6,6’-tetrachloro-1,1’,3,3’-tetraethylbenzimidazolylcarbocyanine iodide (JC-1) staining in 
both CGSD SH-SY5Y cells (a–d) and Aβ1–42-treated HT-22 cells (e–h), Representative fluorescent photomicrographs are shown (a–c; e–g). 
Scale bars represent 10 µm. Mitochondrial accumulation of JC-1 is demonstrated by the red fluorescence and cytoplasmic JC-1 monomers 
are observed as green fluorescence. Bar graphs quantifying average J-aggregates/J-monomers ratio of CGSD SH-SY5Y cells with/without 
10 or 0.1 nM leptin treatment (d) and Aβ1–42-treated differentiated hippocampal cells with/without 10 or 0.1 nM leptin treatment (h) are also 
shown. Data are presented as means ± SEM with individual data points overlaid onto the graphs to demonstrate the distribution of the data. 
Statistical significance is denoted by * and ***, representing p < .05 and p < .001 respectively
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fragmentation is sensitive for fragmented to normal short tubular 
mitochondria. Taken together, these indices provide a thorough in-
vestigation of mitochondrial morphology.
From this quantification of mitochondrial morphology, it was 
demonstrated that serum and glucose withdrawal for 72 hr increased 
the index of fragmentation, which accords with the above subjective 
observations. Treatment with leptin at 10 and 0.1 nM prevented 
CSGD-induced mitochondrial fission by significantly decreasing the 
fragmentation index (p < .05, Kruskal–Wallis with Dunn's post hoc 
test, Figure 2e) and highly significantly increasing the mitochon-
drial index of interconnectivity (p < .01 for 10 nM leptin treatment; 
p < .001 for 0.1 nM leptin treatment, one-way ANOVA with Dunn's 
post hoc test, Figure 2f). Taken together, leptin is sufficient to pre-
vent increased mitochondrial fragmentation induced by CGSD.
3.3 | Leptin prevents increased mitochondrial 
fragmentation in an in vitro AD model
Figure 3 shows the representative mitochondrial morphology of dif-
ferentiated hippocampal HT-22 neuronal cells in different conditions 
(Figure 3a–d). In untreated control HT-22 hippocampal neuronal 
cells, the majority of mitochondria are short and tubular (Figure 3a). 
After treatment with 10 µM Aβ1–42 for 24 hr, mitochondria become 
fragmented, small and punctate (Figure 3b). Following 24 hr of co-
treatment with leptin, this effect was largely absent (Figure 3c,d). 
Indeed, the majority of mitochondria in leptin-treated neuronal cells 
retained their short tubular morphology.
Leptin treatment prevented the increased index of fragmenta-
tion induced by Aβ1–42, but significant differences were only ob-
served with 0.1 nM leptin and not 10 nM leptin (p < .01, one-way 
ANOVA with Dunn's post hoc test, n ≥ 60, Figure 3e). Mitochondria 
in HT-22 are much smaller than that in SH-SY5Y and a complex 
mitochondrial network is seldom seen in these hippocampal cells. 
Therefore, instead of calculating index of interconnectivity, an index 
of elongation was calculated by adopting the inverse of circularity. 
Leptin treatment significantly increased the index of elongation 
in Aβ1–42-treated cells significantly (p < .05, one-way ANOVA with 
Dunn's post hoc test, n ≥ 60, Figure 3f). Taken together, leptin is 
sufficient to prevent mitochondrial fragmentation induced by Aβ1–42 
and promote mitochondrial elongation. This, in conjunction with the 
data on the ΔΨm, strengthens the evidence that leptin protects mi-
tochondrial function in models of ischaemic stroke and AD in vitro 
by regulating mitochondrial dynamics.
F I G U R E  2   Leptin treatment protects against mitochondrial fragmentation induced by combined glucose and serum deprivation 
(CGSD). Representative images of mitochondrial morphology in 72 hr CGSD SH-SY5Y cells with/without 10 or 0.1 nM leptin treatment 
are shown (a–d), with expanded views shown (ai–di). In untreated SH-SY5Y cells, the predominant mitochondrial morphology is short and 
tubular (a, ai). 72 hr CGSD results in the mitochondrial network becoming fragmented and staining appears more punctate. There is also 
notable mitochondrial swelling (b, bi). Leptin treatment inhibits CGSD mitochondrial fragmentation and promotes mitochondrial fusion. 
Thus, mitochondria are tubular in leptin-treated cells (c–d, ci–di). Bar graphs demonstrate mitochondrial morphology, quantified by two 
independent variables: index of mitochondrial fragmentation (e) and interconnectivity (f), with individual data points overlaid onto the graph 
to demonstrate the variability of the data. Data are presented as means ± SEM. N ≥ 200 cells. *, ** and *** represent statistical significance at 
p < .05, p < .01 and p < .001 respectively. Scale bars represent 10 µm (a–d) and 2 µm (ai–di)
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3.4 | Leptin balances mitochondrial dynamics by 
regulating the expression of mitochondrial fission and 
fusion proteins
To explore the molecular mechanism by which leptin regulates the 
dynamics of neuronal mitochondria in vitro, changes of mitochon-
drial fission and fusion protein expression were studied using ELISA. 
Proteins involved in mitochondrial fission (Fis1 and Drp1) and fusion 
(Mfn1 and Mfn2) were examined. In CGSD SH-SY5Y cells leptin at 
10 and 0.1 nM significantly decreased the expression of Fis1 com-
pared to CGSD (p < .001, one-way ANOVA with Dunn's post hoc 
test; n ≥ 4, Figure 4b). In these experiments, because of the variation 
in the degree of cell death induced by CGSD, data are compared to 
CGSD rather than to untreated control. In addition, 0.1 nM leptin 
treatment significantly increased the expression of Mfn2 in com-
parison to CGSD (p < .05, one-way ANOVA with Dunn's post hoc 
test, n ≥ 4, Figure 3d). No significant differences were observed in 
Drp1 (p = .5724, one-way ANOVA with Dunn's post hoc test, n ≥ 4, 
Figure 4a) or Mfn1 (p = .8214, one-way ANOVA with Dunn's post 
hoc test, n ≥ 4, Figure 5). These results reveal that leptin prevents 
CGSD-induced changes to mitochondrial morphology by reducing 
Fis1 expression and increasing Mfn2 expression, which is associated 
with decreased fragmentation and enhanced interconnectivity of 
the mitochondrial network respectively.
Changes in expression levels of mitochondrial fission and fusion 
proteins in Aβ1–42-treated HT-22 hippocampal cells are also shown 
(Figure 4e–h). The expression of Drp1 and Fis1 was increased in Aβ1–
42-treated HT-22 neuronal cells compared to untreated control. This 
effect was abolished by co-administration of 0.1 nM leptin (p < .05, 
one-way ANOVA with Dunn's post hoc test,n ≥ 4, Figure 4e–f). 
However, the effect of 10 nM leptin treatment was not significant 
after post hoc analysis. In addition, the increased level of Mfn1 in 
Aβ1–42-treated cells was abolished by leptin treatment and was sig-
nificant at 0.1 nM (p < .05, one-way ANOVA with Dunn's post hoc 
test,n ≥ 4, Figure 4g). Levels of Mfn2 were increased in all condi-
tions and leptin did not ameliorate these changes in Aβ1–42-treated 
cells (p = .7252, one-way ANOVA with Dunn's post hoc test,N ≥ 4, 
Figure 4h). These results suggest that leptin prevents Aβ1–42-induced 
changes to mitochondrial morphology by reducing the expression of 
Drp1 and Fis1, and increasing the expression of Mfn1, thereby pre-
venting fragmentation of the mitochondrial network.
To confirm our findings from the ELISA assays, immunocyto-
chemistry was adopted to visualize the expression of Fis1 following 
CGSD with or without exogenous leptin administration. As shown 
in Figure 5, the fluorescent labelling and therefore expression of 
Fis1 following 72 hr CGSD (upper panels) was markedly decreased 
in 0.1 nM leptin co-treated cells (Figure 5a, lower panels). Cells were 
co-stained with MitoRed to allow visualisation of the mitochondrial 
network (Figure 5a). Merged images demonstrating co-localisation 
of the Fis1 immunoreactivity and the mitochondria are shown. To 
aid visualisation expanded views of individual cells are also shown 
(Figure 5b). Quantitative analysis of the immunocytochemistry im-
ages was performed. 0.1 nM leptin significantly decreased Fis-1 ex-
pressing in CGSD neural cells as compared to those that had not had 
leptin treatment (p < .001, t-test, n > 200 cell per condition from at 
least three separate plate downs, Figure 5c). Control stainings lack-
ing the primary antibody did not exhibit the robust green fluores-
cence (Figure S1) confirming the specificity of the antibody.
Similarly, immunocytochemical analysis of Mfn2 expression 
was undertaken in these cells (Figure 6). Mfn2 immunoreactivity 
F I G U R E  3   Leptin treatment protects against abnormal 
mitochondrial fragmentation induced by Aβ1–42. Representative 
images of mitochondrial morphology in 24 hr Aβ1–42-treated 
HT-22 cells with/without 10 or 0.1 nM leptin treatment (ai-di) 
and digitally expanded views are shown (aii–dii). The expanded 
areas are denoted by the white quadrangles on ai–di. In untreated 
differentiated HT-22 cells, the predominant mitochondrial 
morphology is short and tubular (a). Mitochondria in 24 hr Aβ1–42-
treated cells become fragmented and become punctate (b). Leptin 
inhibits Aβ1–42-triggered mitochondrial fragmentation and promotes 
mitochondrial fusion. Mitochondria are predominantly observed as 
short and tubular in leptin and Aβ1–42 co-treated cells (c–d). Scale 
bar represents 30 µm with the scale bar on the expanded views 
representing 5 µm. The bar graphs show mitochondrial morphology 
quantified by two independent variables: indices of mitochondrial 
fragmentation (e) and elongation (f). Data are presented as 
means ± SEM, with individual data points overlaid onto the graphs 
to demonstrate the distribution of the data. N ≥ 200 cells across 
the three separate experimental repeats. *, ** and *** represent 
statistical significance at p < .05, p < .01 and p < .001 respectively
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after 72 hr CGSD was increased in 0.1 nM leptin treated cells 
(Figure 6a, lower panels). This is in keeping with the ELISA data 
(Figure 4). Cells were co-stained with MitoRed to allow visuali-
sation of the mitochondrial network (Figure 6a). Merged images 
demonstrating co-localisation of the Mfn2 immunoreactivity and 
the mitochondria are also shown. To aid visualisation expanded 
views of individual cells are also shown (Figure 6b). Quantitative 
analysis of the immunocytochemistry images was performed. 
Percentage areas of Mfn2 staining within the mitochondrial net-
work were calculated. 0.1 nM leptin significantly increased Mfn2 
expression in CGSD neural cells (p < .001, t test, n > 200 cells per 
condition from at least three separate plate downs, Figure 6c). 
Control stainings lacking the primary antibody did not exhibit ro-
bust green fluorescence (Figure S2) confirming the specificity of 
the Mfn2 antibody.
3.5 | Leptin regulates enzymes involved in 
ROS production
Our findings this far demonstrate that leptin inhibits mitochondrial 
fragmentation in both a CGSD ischaemic stroke model and in an 
in vitro model of AD by modulating the expression of proteins in-
volved in regulating mitochondrial dynamics. To expand upon these 
finding we next examined the effects of leptin on proteins involved 
in inducing mitochondrial biogenesis and oxidative stress-related 
enzymes (Figure 7). PGC1-α, a central inducer of mitochondrial 
biogenesis, induces the expression of nuclear respiration factor-1 
(NRF-1). PGC1-α is also a powerful regulator of ROS removal. In 
CGSD human neural cells, we discovered that leptin (10 or 0.1 nM) 
decreased the expression of NRF1 (p < .01, one-way ANOVA, n ≥ 4, 
Figure 7b). No significant differences in PGC1-α in leptin-treated 
cells were observed (p = .1196, one-way ANOVA, n ≥ 4, Figure 7a). 
Monoamine oxidases (MAO-A/B) are enzymes that are responsi-
ble for the metabolism of monoamine neuro-transmitters, are in-
volved in production of ROS. In CGSD cells, 0.1 nM leptin decreased 
the levels of MAOB (p < .01, one-way ANOVA, n ≥ 4, Figure 7c) 
significantly in comparison to CGSD, however, we found no sig-
nificant differences of MAO-A expression with leptin administra-
tion (p = .8199, one-way ANOVA, n ≥ 4, Figure 7d). To determine 
whether this decrease in MAOB expression resulted in a decrease 
in the activity of the monoamine oxidase enzymes, we conducted 
an MAO activity assay as reported previously (Zhou et al., 1997). 
We uncovered that 01 nM leptin significantly decreases the activity 
of MAO compared to CGSD alone (p < .05, one-way ANOVA, n = 7, 
Figure 7e).
In Aβ1–42-treated HT-22 cells, neither the expression of 
PGC1-α (p = .3791, one-way ANOVA, n ≥ 4, Figure 7f) nor NRF1 
F I G U R E  4   Leptin protects against dysregulation of fission and fusion protein expression induced by combined glucose and serum 
deprivation (CGSD) or Aβ1–42. Bar graphs (a–d) show the data from ELISAs to determine the effects of leptin administration on the 
expression levels of mitochondrial fission proteins (Drp1 (a) and Fis1 (b)) and fusion proteins (Mfn1 (c) and Mfn2 (d)) relative to the 
CGSD condition in SH-SY5Y cells. Corresponding bar graphs for hippocampal cells (e–h) are also presented showing the effects of leptin 
administration on the expression levels of mitochondrial fission proteins (Drp1 (e) and Fis1 (f)) and fusion proteins (Mfn1 (g) and Mfn2 
(h)) relative to the cells treated with Aβ alone. Data are presented as means ± SEM, with n ≥ 4 experimental repeats for each protein. The 
distribution of the data derived from the individual experimental repeats is demonstrated by the individual data points on each bar. Each 
experimental data point represents the mean of three technical repeats for each sample. Statistical significance is denoted by *, ** and ***, 
representing p < .05, p < .01 and p < .001 respectively
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(p = .6996, one-way ANOVA, n ≥ 4, Figure 7g) were significantly 
altered. However, both MAO-A and MAO-B expression were 
increased significantly in Aβ1–42-treated hippocampal neurons, 
exhibiting around a 50% increase compared to untreated con-
trol neurons (Figure 7h–l). Co-treating Aβ1–42-treated hippo-
campal neurons with leptin for 24 hr, significantly reduced the 
increase in MAO-A (p < .01, one-way ANOVA, n ≥ 4, Figure 7h) 
and MAO-B (p < .01, one-way ANOVA, n ≥ 4, Figure 7i). These 
results indicate that leptin down-regulates enzymes involved 
in the production of ROS that may contribute to its protection 
against mitochondrial dysfunction in models of ischaemic stroke 
and AD in vitro.
3.6 | Leptin inhibits Aβ1–42-induceded neuronal 
membrane permeability and prevents loss of 
neuronal viability
It is well established that leptin protects against CGSD in SH-SY5Y 
neural cells (Russo, Metaxas, Kobayashi, Harris, & Werther, 2004) 
and therefore our results can be interpreted to be part of the known 
neuroprotective actions of this hormone in these cells. In contrast, it 
has never been demonstrated that leptin protects against neuronal 
cell death in fully differentiated HT-22 hippocampal cells. Therefore 
we aimed to elucidate leptin's potential as a neuroprotectant in this 
model. Treating differentiated HT-22 mouse hippocampal neurons 
F I G U R E  5   Leptin decreases Fis1 expression in combined glucose and serum deprivation (CGSD) SH-SY5Y cells. Representative 
photomicrographs of CGSD SH-SY5Y cells (ai–iii; bi–iii) and those also treated with 0.1 nM leptin (aiv–vi and biv–vi). Single channel images 
of MitoRed (shown in red) or Fis1 (shown in green) staining are presented along with the merged image and digitally expanded views (b). 
The merged views confirm that the Fis1 immunoreactivity is mitochondrial. The expanded areas are denoted by the white quadrangles 
on aiii and avi. Scale bar represents 20 µm with the scale bar on the expanded views representing 10 µm. Bar graph demonstrates the 
outcome of quantitative analysis Fis1 expression within the mitochondrial network (c). Individual data points are overlaid on the chart to 
allow visualisation of the distribution of individual data points. Data are presented as mean ± SEM. N ≥ 200 cells from three independent 
experiments and *** represents significance at p < .001
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with Aβ1–42 (10 µM) results in the release of LDH, which indicates 
damaged membrane permeability. Leptin treatment at 10 and 
0.1 nM significantly decreased the release of LDH induced by Aβ1–42 
significantly (Figure 8 one-way ANOVA, p < .05, n = 6). These data 
demonstrate that leptin ameliorates neuronal membrane perme-
ability induced by Aβ1–42. In addition, treating hippocampal neurons 
with Aβ1–42 leads to 13.5% decrease of neuronal number, as deter-
mined by crystal violet assay, compared to an untreated control. 
Leptin treatment at both 10 and 0.1 nM significantly reduced the 
Aβ1–42-mediated decrease in cell number (Figure 8 one-way ANOVA, 
p < .05, n = 8). Taken together, leptin ameliorates neuronal loss, in-
hibits abnormal membrane permeability and promotes hippocampal 
neuronal viability induced by treatment with Aβ1–42.
4  | DISCUSSION
Leptin, known as an essential mediator of energy homeostasis, exerts 
a protective role in models of neurodegenerative diseases, including 
AD (Doherty, 2011; Li, Yan, Guo, & Wang, 2016). Epidemiological 
F I G U R E  6   Leptin increases Mfn2 expression in combined glucose and serum deprivation (CGSD) SH-SY5Y cells. Representative 
photomicrographs of CGSD SH-SY5Y cells (ai–iii; bi–iii) and those also treated with 0.1 nM leptin (aiv–vi and biv–vi). Single-channel images 
of MitoRed (shown in red) or Mfn2 (shown in green) staining are presented along with the merged image and digitally expanded views (b). 
The merged views confirm that the Mfn2 immunoreactivity is mitochondrial. The expanded areas are denoted by the white quadrangles (aiii 
and avi). Scale bar represents 20 µm, with the scale bar on the expanded view representing 10 µm. Bar graph demonstrates the outcome of 
quantitative analysis of Mfn2 (c). Individual data points are overlaid on the chart to allow visualisation of the distribution of the data. Data 
are presented as mean ± SEM. N ≥ 200 cells from three independent experiments and *** represents significance at p < .001
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studies have revealed that higher serum leptin levels protect against 
cognitive impairment (Holden et al., 2009; Witte et al., 2016) and are 
associated with a reduced incidence of AD (Gilbert et al., 2018; Lieb 
et al., 2009). Expression of Ob-Rb is decreased and leptin signalling 
(Akt) disrupted in the hippocampus of APP/presenilin 1 mice (King 
et al., 2018) further implicating leptin signalling in AD pathogenesis. 
In addition, leptin treatment is capable of attenuating pathological 
deposition of Aβ and phosphorylated tau in AD models (Guo et al., 
2016; Liu, Zhang, Liu, & Yin, 2017; Marwarha, Dasari, Prasanthi, 
Schommer, & Ghribi, 2010). Furthermore, increased mitochondrial 
ROS and damaged ΔΨm are observed in brains of diet-induced 
obese rats (Ma, Yuan, Yu, Xi, & Xiao, 2014) that lack efficient lep-
tin signalling because of leptin resistance (Scarpace & Zhang, 2009). 
Mitochondrial degeneration in the blood–brain barrier has been 
F I G U R E  7   Leptin regulates the expression and activity of mitochondrial biogenesis enzymes and monoamine oxidase (MAO). Bar graphs 
(a–d) show ELISA data determining the effects of leptin administration on the expression levels of mitochondrial biogenesis proteins, 
PGC1α (a) and NRF1 (b) and monoamine oxidases, MAOA (c) and MAOB (d) relative to the combined glucose and serum deprivation (CGSD) 
condition in SH-SY5Y cells. The effects of leptin administration on MAO activity in these cells is also presented (e). Corresponding bar 
graphs for the expression levels hippocampal cells (f–i) are also presented showing the effects of leptin administration on the expression 
levels of mitochondrial biogenesis proteins, PGC1α (f) and NRF1 (g) and monoamine oxidases, MAOA (h) and MAOB (i) relative to the 
cultures treated with Aβ1–42 alone. Data are presented as means ± SEM, with n ≥ 4 experimental repeats for each protein. The distribution of 
the data derived from the individual experimental repeats is demonstrated by the individual data points on each bar. Each experimental data 
point represents the mean of three technical repeats for each sample. Statistical significance is denoted by * and **, representing p < .05, and 
p < .01 respectively
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detected in db/db mice with leptin receptor deficiency (Corem, 
Anzi, Gelb, & Ben-Zvi, 2019). It is well established that mitochon-
drial dysfunction presents as an early and predominant feature in 
the development of AD (Hauptmann et al., 2009), and promotes the 
pathophysiology of AD (Cheng & Bai, 2018). Thus the potential for 
leptin to benefit mitochondria has numerous potential clinical appli-
cations. However, the effect of leptin on mitochondrial function in 
the early and late stages of AD has not been examined.
Our study provides compelling evidence that leptin exerts its 
known neuroprotective role through balancing mitochondrial mor-
phological dynamics and improving mitochondrial dysfunction in 
AD-linked cell models. Thus leptin ameliorates increased mito-
chondrial fragmentation through regulating the expression of mi-
tochondrial fission and fusion proteins, and prevents the loss of 
mitochondrial membrane potential induced by Aβ1–42.
The neurobeneficial effects of leptin have long been known, 
with the first reports revealing leptin's anti-apoptotic actions in SH-
SY5Y neural cells in vitro (Russo et al., 2004). We have expanded on 
this to reveal that leptin protects differentiated HT-22 hippocam-
pal neurons from Aβ1–42-mediated neurotoxicity. Thus in both our 
CGSD SH-SY5Y human neuroblastoma cells, an ischaemia stroke 
model (Lorenz et al., 2009) and in Aβ1–42-treated differentiated 
HT-22 hippocampal neuronal cells, an AD model, leptin protects 
against cell death. The concentrations of leptin that we have used 
in this investigation are within the low nanomolar physiological 
range (0.1–10 nM; Moult et al., 2010). However, the data reveal that 
the lower concentration (0.1 nM) is more effective than 10 nM ad-
ministration in mediating leptin's neurobeneficial actions. The pos-
sibility that there is endogenous secretion of leptin in the cultures, 
pushing the true concentration into a supraphysiological range with 
the higher concentration treatment cannot be discounted. Indeed 
HT-22 cells have recently been shown to up-regulate the leptin 
transcript following hydrogen sulphide administration (Zhu et al., 
2019) and SH-SY5Y cells are known to express endogenous leptin 
(Marwarha, Dasari, & Ghribi, 2012). Nonetheless, in our study the 
effects of administering physiological doses of leptin on the mito-
chondrial network as clear.
Maintaining balanced mitochondrial dynamics is an essential pro-
cess, which promotes mitochondrial distribution across axons into 
synapses and separates damaged mitochondrial constituents, to meet 
high neuronal energy demand and facilitate protective effects (Diaz & 
Moraes, 2008; Scott, Youle, Pike, Lee, & Yoon, 2016). Unbalanced dy-
namics is hypothesised to be an essential mechanism leading to syn-
aptic and neuronal dysfunction in AD (Santos et al., 2010; Wang et al., 
2009, 2014). In our study, we reveal that leptin inhibits mitochondrial 
fission induced by CGSD and Aβ1–42, and promotes mitochondrial 
fusion balancing the morphological dynamics and improving mito-
chondrial dysfunction. In previous studies, it was found that over-ex-
pression of Fis1 and decreased levels of Mfn1, Mfn2, Drp1 and OPA1 
led to the impaired balance of mitochondrial fission/fusion dynamics 
in an in vitro AD model (Wang et al., 2008, 2009). In agreement with 
these previous studies, up-regulation of Fis1 was observed in neu-
ronal cells induced by AD-linked insults Aβ1–42 and CGSD. Moreover 
expression of Drp1 was also increased in Aβ1–42-treated hippocampal 
neurons. A recent study supports the possibility that interaction of 
Drp1/Fis1 in mitochondria leads to excessive mitochondrial fission 
and neuronal injury in AD (Joshi, Saw, Shamloo, & Mochly-Rosen, 
2018). We found that over-expression of Fis1 and Drp1 was linked 
to excessive mitochondrial fragmentation in Aβ1–42-treated neuronal 
cells. Leptin inhibited the over-expression of Fis1 in CGSD neural cells, 
and for both Drp1 and Fis1 the increased levels induced by Aβ1–42 
were decreased by leptin treatment. Thus leptin decreases the ex-
pression of mitochondrial fission proteins in our experiments.
Depletion of fusion protein Mfn2 results in excessive mitochon-
drial fission and cellular death in cortical neurons (Uo et al., 2009). 
Human Mfn2 mutations cause mitochondrial network fragmen-
tation (Rocha et al., 2017), and leptin treatment increases the ex-
pression of Mfn2 and Drp1, modulating mitochondrial dynamics in 
MCF-7 breast cancer cells (Blanquer-Rossellõ et al., 2015). Here we 
show that in addition to the known data from the breast cancer cell 
line, leptin also increases the expression of Mfn2 in CGSD neural 
cells. No significant increases in Mfn levels were discovered in the 
Aβ1–42-treated hippocampal neurons, but these cells have a less in-
terconnected mitochondrial network in the untreated condition as 
F I G U R E  8   Leptin inhibits Aβ1–42-mediated increased neuronal membrane permeability and increases neuronal viability in hippocampal 
cells. Bar graphs showing effects of leptin administration on the release of lactate dehydrogenase (LDH) into cell culture relative to Aβ1–42 
treatment alone (a), and the output of a crystal violet assay for cell number demonstrating cell viability relative to that observed in control, 
untreated cultures (b), are presented. Data are presented as means ± SEM. N ≥ 6 independent experiments; * and ** represent statistical 
significance at p < .05 and p < .01 respectively. Individual data points have been overlaid onto the bar charts to reveal the distribution of the 
data gathered
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compared to the SH-SY5Y cell line and therefore a lesser degree of 
fusion may be required to maintain the normal mitochondrial mor-
phology. In summary, our results show that leptin inhibits abnormal 
mitochondrial fission in AD models by down-regulating Fis1 and 
Drp1 and up-regulating Mfn2.
Furthermore, mitochondrial biogenesis, a process in which 
PGC1-α is a central inducer, contributes to the maintenance of 
the healthy mitochondrial population. PGC1-α also regulates the 
removal of ROS (Austin & St-Pierre, 2012), and increases the ex-
pression and activity of NRF1, a transcription factor that medi-
ates production of nuclei-encoded mitochondrial genes coding 
for subunits of the oxidative phosphorylation system (Virbasius, 
Virbasius, & Scarpulla, 1993; Wu et al., 1999). However, we show 
here that mitochondrial biogenesis is not a powerful regulator 
in leptin-mediated mitochondrial dynamics balance, with no dif-
ferences in the level of expression of proxisome proliferator-ac-
tivated receptor γ coactivator 1 in either in vitro model. NRT-1 
expression is decreased by leptin treatment in CGSD-treated cells 
but not in the Aβ1–42-treated cells. As NRF-1-mediated changes 
in gene expression are linked to protection from oxidative stress 
(Hertel, Braun, Durka, Alzheimer, & Werner, 2002), it could be 
hypothesised that a protective agent might up-regulate this pro-
tein. Taken together we did not find any evidence that proxisome 
proliferator-activated receptor γ coactivator 1 and/or activation of 
NRF-1 contribute to the neuroprotective actions of leptin.
Because of the production of hydrogen peroxide and induced 
oxidative stress, excessive MAO activity is regarded as a risk factor 
in AD (Quartey et al., 2018). Indeed, inhibition of MAO has been 
proposed as a treatment target in AD (Hroch et al., 2017; Naoi & 
Maruyama, 2010). We provide here the first evidence that leptin 
inhibits the expression and activity of MAO in AD models, imply-
ing the involvement of leptin in protection against oxidative stress 
through modulation of this enzyme. In addition, MAO regulates 
mitochondrial fission in cardiomyocytes during aging (Vigneron, 
Guilbeau-Frugier, Parini, & Mialet-Perez, 2013). In our hands leptin 
significantly down-regulated MAOB in CGSD cultures and the Aβ1–
42-treated hippocampal neurons, with MAOA down-regulated in 
the latter population as well. The large volume of protein that can 
be derived from the SH-SY5Y cultures allowed us to further inves-
tigate this and determine that there is a functional consequence of 
this down-regulation of protein expression with a marked decrease 
in MAO activity detected in the MAO activity assay. Unfortunately 
the nature of the differentiated hippocampal cultures is such that it 
is not possible to harvest the highly concentrated protein samples 
required for the assay at sufficient volume and therefore we could 
not confirm this finding in these cells. Nonetheless, we demon-
strate a robust down-regulation of expression of MAO enzymes 
in Aβ1–42-treated hippocampal cells revealing that leptin can target 
the MAO system, a previously proposed therapeutic goal for AD 
treatment (Hroch et al., 2017; Naoi & Maruyama, 2010).
The maintenance of a normal ΔΨm is important for optimal mi-
tochondrial function (Zorova et al., 2017). In recent developments of 
mitochondria-targeted therapeutics for neurodegenerative disease, 
antioxidant drugs such as MitoQ and peptide SS take advantage of the 
ΔΨm to accumulate in mitochondria and implement their protective 
role (Birk, Chao, Bracken, Warren, & Szeto, 2014; Snow et al., 2010). 
However, two facts should be taken into consideration. Dysfunctional 
mitochondria tend to have disrupted ΔΨm, which may limit the intake 
of drugs. Excessive uptake of drugs driven by ΔΨm may result in a de-
pressed ΔΨm (Wang & Chen, 2016). Here we show that leptin regulates 
enzymes that protect against oxidative stress and protects mitochon-
drial function without depending on or damaging ΔΨm. However, it 
does restore a depleted ΔΨm thereby benefitting mitochondrial func-
tion, further underpinning the beneficial effects of leptin.
Our data reveal that leptin is a potential therapeutic target for 
disorders, such as AD, where mitochondrial dysfunction has been 
intricately linked to pathogenesis. It is likely that leptin-based 
therapeutics would not be suitable for all patients as it is known 
that some individuals exhibit leptin resistance which would inhibit 
their responsiveness to a class of drugs based on this hormone 
(Liu, Yang, Yu, & Zheng, 2018). Nonetheless, given the proven re-
duced circulating leptin levels in AD patients (Lieb et al., 2009) and 
the emerging knowledge of compounds such as celastrol that can 
sensitise individuals to leptin's effects (Chellappa, Perron, Naidoo, 
& Baur, 2019), this remains a crucial pathway to explore in the 
search for anti-degenerative therapeutics. Leptin is a large mole-
cule and is hard to administer, requiring subcutaneous injections. 
Pharmaceutical work on leptin mimetics has been undertaken and 
promising bioactive fragments such as leptin 116–130 that retain 
the CNS actions of leptin have been uncovered (Malekizadeh et al., 
2017). Further development of this region of the molecule into 
an orally deliverable preparation, [D-Leu-4]-OB3, that crosses the 
blood–brain barrier (Anderson, Jacobson, Novakovic, & Grasso, 
2017) suggest that overcoming the administration difficulties of 
the full length molecule offer an exciting avenue in development 
of leptin as a therapeutic. Further work to investigate whether 
these small fragments of the leptin molecule mirror its beneficial 
effects on the mitochondrial network are therefore an area of re-
search that warrants future exploration.
In conclusion, these findings provide compelling evidence that 
leptin protects against early mitochondrial dysfunction and against 
Aβ1–42-induced aberrant mitochondrial dynamics in two established 
AD-related cellular models. This further underlines the essential role 
of mitochondrial dysfunction in AD and also identifies a novel pro-
tective role of leptin in the regulation of mitochondrial dynamics.
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